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This study investigated the antispasticity potential of Sativex in mice. Chronic relapsing experimental allergic encephalomyelitis
was induced in adult ABHmice resulting in hind limb spasticity development. Vehicle, Sativex, and baclofen (as a positive control)
were injected intravenously and the “stiﬀness” of limbs assessed by the resistance force against hind limb flexion. Vehicle alone
caused no significant change in spasticity. Baclofen (5mg/kg) induced approximately a 40% peak reduction in spasticity. Sativex
dose dependently reduced spasticity; 5mg/kg THC + 5mg/kg CBD induced approximately a 20% peak reduction; 10mg/kg
THC + 10mg/kg CBD produced approximately a 40% peak reduction in spasticity. Sativex has the potential to reduce spasticity
in an experimental mouse model of multiple sclerosis (MS). Baclofen reduced spasticity and served as a positive control. Sativex
(10mg/kg) was just as eﬀective as baclofen, providing supportive evidence for Sativex use in the treatment of spasticity in MS.
1. Introduction
Spasticity may be best understood as an increase in muscle
tone leading to muscle hypertonia and exaggerated tendon
reflexes [1]. It is a painful symptom that develops during
multiple sclerosis (MS) and spinal cord injury, where damage
to the nervous system results in uncontrolled limb motor
function [2]. Like most other symptoms of MS, spasticity
is caused as a result of demyelination and nerve loss within
neural circuitry [3]. There are several types of spasms that
aﬀect people with MS. They tend to be asymmetrical and,
due to slow or interrupted nerve impulses, muscles either do
not relax as quickly as they should, tighten involuntarily, or
stay contracted for longer periods of time [2]. Spasticity is a
significant problem for around 60% of MS patients [1], and
it has been estimated that one-third of people with MS alter
their daily activities due to spasticity [3].
Current forms of treatment for people suﬀering
from MS-related spasticity include physical therapy, which
involves stretching and hydrotherapy, employment of
mechanical aids, such as braces, use of chemical blocks
including phenol injected into the muscles or intrathecally,
or in extreme cases, surgery [4, 5]. The most common
form of treatment is the use of oral medications, but
current therapy is often associated with dose-limiting adverse
side-eﬀects. Approximately 37% of MS patients take the
most commonly prescribed antispasticity agents [2] includ-
ing baclofen, dantrolene, tizanidine, diazepam, gabapentin,
botulinum toxin, and phenol, but many clinicians report
that a proportion of these patients are not being adequately
treated due to adverse eﬀects of these medications.
For the same reason, some patients have turned to
self-medication and have perceived benefit from cannabis
[6]. Sativex (nabiximols) is derived from extracts of the
2 ISRN Neurology
Cannabis sativa Linnaeus plant, with a 1 : 1 mixture of delta-
9-tetrahydrocannabinol (THC) and cannabidiol (CBD) as
the main active substances, delivered as an oromucosal
spray. The principal pharmacological eﬀects of THC include
analgesic, muscle relaxant, antiemetic, appetite stimulant,
and psychoactive eﬀects [7]. CBD has anticonvulsant, mus-
cle relaxant, anxiolytic, neuroprotective, antioxidant, and
antipsychotic activity [8], though its importance lies not only
in its own inherent therapeutic profile but also in its ability
to modulate some of the undesirable eﬀects of THC through
both pharmacokinetic and pharmacodynamic mechanisms
[9].
Sativex has recently been licensed for the treatment of
spasticity in MS following a number of positive clinical trials
[10]. A meta-analysis of 666 patients with MS who had
spasticity that was not adequately controlled using existing
treatments and were then given Sativex (n = 363) or placebo
(n = 303) showed that there was a definite reduction in
patient reported problems, that the eﬀects of Sativex were
usually evident within three weeks, and that about one-third
of people given Sativex as an add-on treatment gained at least
a 30% improvement from baseline [11]. Similarly, a double-
blind, randomized trial of Sativex in 337 subjects with
symptoms of spasticity due to MS demonstrated that Sativex
treatment resulted in a significant reduction in treatment-
resistant spasticity [12].
The cannabinoids within Sativex target the cannabinoid
receptors, designated CB1 and CB2, which are concentrated
in the central nervous system (CNS) and peripheral termi-
nals of primary aﬀerent neurons and the immune system
[13]. The cannabinoid system consists of a number of
endogenous fatty acid ligands together with biosynthetic and
degradation systems and has been shown to regulate synaptic
neurotransmission [14, 15]. Therefore, it may be anticipated
that Sativex would control spasticity, which is a product
of uncontrolled nervous signaling. We investigated this by
assessing the eﬀect of the botanical drug substances (BDSs),
which comprise Sativex in spasticity in chronic relapsing
experimental autoimmune encephalomyelitis (CREAE), an
animal model of MS [16]. A cannabis extract containing
20% THC but no CBD has previously been shown to treat
experimental spasticity in EAE at a dose of 5mg/kg i.v. [17].
However, a 1 : 1 mix of CBD : THC was chosen for this study
as this is the medicinal product currently licensed and used
for the treatment of spasticity in patients with MS, with
all the associated benefits that the combination of the two
cannabinoids provide to patients in a clinical setting.
2. Materials and Methods
2.1. Animals. Adult (20–25 g; 6–8 weeks old) Biozzi ABH
mice were bred at Queen Mary University of London or
purchased from Harlan-Olac UK, (Bicester, UK). Animals
received a subcutaneous injection of 1mg freeze-dried
mouse spinal cord homogenate in Freund’s adjuvant supple-
mented with 60 µg Mycobacterium tuberculosis and Mycobac-
terium butryicum (8 : 1) in the flank on Days 0 and 7 as
described previously [16]. This induced the development of
a relapsing-remitting paralytic disease with the accumulation
of an increasing neurological deficit. Assessment of tremor
and spasticity involves the use of animals in remission,
usually after the second or third relapse 40–80 days after
inoculation [18]. In this study, mice were used 7-8 months
after inoculation. Again they were in postrelapse remission
and exhibited paresis and visual evidence of spasticity [18]
but by this stage, were very severely aﬀected. The mice with
residual paresis and visible evidence of spasticity during
postrelapsing progressive EAE were then randomized into
four parallel groups (n = 6–8 per group) that were treated
with either: 1 : 1 THC : CBD at a dose of 5mg/kg, 1 : 1
THC : CBD at a dose of 10mg/kg, baclofen at a dose of
5mg/kg as a positive control, or vehicle alone.
2.2. Compounds. BDSs containing high levels of either THC
(69.3%) or CBD (66.5%) were supplied by GW Pharma Ltd.
and held under a Home Oﬃce Licence to Possess under
The Misuse of Drugs Act 1971. These were combined in
a 1 : 1 ratio based on the amount of principal cannabinoid
within each BDS, then dissolved in ethanol prior to addition
of Cremophor (Sigma, Poole Dorset) and then phosphate-
buﬀered saline (PBS) in a ratio of (1 : 1 : 18). This closely
resembles the composition of Sativex, where the same BDSs
are formulated in a 50 : 50 mixture of ethanol and propylene
glycol, and for simplicity is referred to as Sativex throughout
this paper. Baclofen was purchased from RBI/Sigma (Poole,
UK) and was dissolved in PBS. All compounds were injected
intravenously in the tail vein using a 30 g needle in a volume
of 0.1mL at doses of 5mg/kg or 10mg/kg Sativex and
5mg/kg baclofen. The doses of Sativex used were chosen
on the basis of previous studies [18, 19] and represent a
reasonable equivalence to the clinical dose range used in
human patients.
2.3. Assessment of Eﬀects. The “stiﬀness” of spastic limbs
was assessed by measuring the force required to bend the
hind-limb of each mouse to full flexion using a purpose-
built strain gauge. This evaluation has been used eﬀectively
in numerous previous studies [17, 18, 20–22] and is the
only reported tool for investigating spasticity related to MS
in animals. Moreover, it provides objective and qualitative
readouts. Its application in this study was further validated
by the use of a positive control. Both the left and right hind-
limbs were assessed repeatedly, typically five times per time
point, with the resulting analogue signals being amplified
and then digitized and captured using a DAQcard 1200
PCMICA card (National Instruments Austin, TX, USA) and
Acquire V1 software (D. Buckwell, Insititute of Neurology,
University College London) on the Windows XP platform.
The data were analysed using Spike 2 software (Cambridge
Electronic Design, UK), and the forces were converted to
Newtons (N). Limbs showing severe crossing or flexion were
not analysed and limbs exhibiting flexion forces of less than
0.15N, (i.e., within the range of limb stiﬀness for normal
animals [18]) were not analysed resulting in some animals
or some limbs being excluded from the final data. Taking
this into account, each group contained a minimum of five
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Figure 1: Mean (SEM) change in resistance to flexion force following treatment with (a) Vehicle, (b) 5mg/kg Baclofen, (c) 5mg/kg Sativex
and (d) 10mg/kg Sativex.
animals. A mean score for each limb at each time point was
calculated as well as a groupmean score based on all available
hind-limb data for all available mice within each group. The
results represent the mean ± SEM resistance to flexion force
(N), which were compared using repeated measures analysis
of variance (RM ANOVA) incorporating Student-Newman-
Keuls post hoc test. Statistics were performed using Sigmastat
V3/Sigmpalot V9 software (Systat Software Inc, Hounslow
UK).
3. Results
Vehicle injection failed to induce a significant (P <
0.3) change in the degree of spasticity over a two-hour
observation period (mean [SEM] percentage change from
baseline after 120 minutes = 7.05 [6.63]) (Figures 1(a)
and 2(a)). Baclofen served as a positive control and after
5mg/kg i.v. injection into spastic mice, induced a significant
reduction in the degree of limb stiﬀness compared to
baseline. This was evident within 10 minutes of treatment
(mean [SEM] percentage change from baseline after 10
minutes = −40.71 [8.26]; P < 0.001) and persisted for
the two-hour observation period (mean [SEM] percentage
change from baseline after 120 minutes = −32.51 [4.48];
P < 0.001) (Figures 1(b) and 2(b)). This treatment-induced
marked limpness and hypomotility, as assessed visually in the
recipient mice, is consistent with the mechanism of action of
GABAB receptor agonists.
Treatment with the formulated Sativex BDSs at a dose
of 5mg/kg THC + 5mg/kg CBD i.v. induced a significant
inhibition in the degree of limb stiﬀness. This was evident
within 10 minutes of treatment (mean [SEM] percentage
change from baseline after 10 minutes = −14.99 [3.54];
P = 0.007) and an inhibitory eﬀect could be detected two
hours after administration (mean [SEM] percentage change
from baseline after 120 minutes = −15.25 [5.9]; P = 0.011)
(Figures 1(c) and 2(c)). This treatment induced some mild
sedation, as assessed visually, in the recipient mice which
is consistent with the mechanism of action of CB1 receptor
agonists.
Treatment with the formulated Sativex BDSs at a dose
of 10mg/kg THC + 10mg/kg CBD i.v. induced a significant
inhibition in the degree of limb stiﬀness. This was evident
within 10 minutes of treatment (mean [SEM] percentage
change from baseline after 10 minutes = −21.40 [8.87];
P = 0.002) and maintained for at least two hours
(mean [SEM] percentage change from baseline after 120
minutes = −30.44 [5.45]; P ≤ 0.001) after administration
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Figure 2: Mean (SEM) percentage change from baseline in hindlimb stiﬀness following treatment with (a) Vehicle, (b) 5mg/kg Baclofen,
(c) 5mg/kg Sativex and (d) 10mg/kg Sativex.
(Figures 1(d) and 2(d)). This level of inhibition of spasticity
was comparable to that seen previously with 5mg/kg i.v.
baclofen (Figures 1(b) and 2(b)). This treatment dose
induced some sedation as assessed visually in the recipient
mice, and is again consistent with the mechanism of action
of CB1 receptor agonists.
In summary, vehicle treatment had no eﬀect on spasticity
(Figures 1(a) and 2(a)). Sativex BDSs administered at a
dose of 5mg/kg THC + 5mg/kg CBD i.v. produced an
approximate 20% peak reduction in hind limb stiﬀness
(Figures 1(c) and 2(c)), whereas Sativex BDSs administered
at a dose of 10mg/kg THC + 10mg/kg CBD i.v. produced
an approximate 40% peak reduction in hindlimb stiﬀness
(Figures 1(d) and 2(d)). This was highly comparable with
baclofen administered at a dose of 5mg/kg i.v., which also
produced an approximate 40% peak reduction in hindlimb
stiﬀness (Figures 1(b) and 2(b)). It, therefore, took a higher
dose of Sativex compared with baclofen to achieve the same
reduction in spasticity; however on a mg per mg basis,
Sativex BDSs were observed to be better tolerated than
baclofen as baclofen-treatedmice were muchmore immobile
than the Sativex BDS-treated animals. This was, however,
a very subjective finding based on observation alone, and
mouse movement in the cage was not actually quantified.
It should also be noted that for mice receiving baclofen
or either of the Sativex doses, the resulting reduction in
spasticity was still very much in eﬀect two hours after dose.
Given the chronic nature of spasticity due toMS and the need
of patients for ongoing treatment, any future studies could
provide invaluable information about the duration of action
of Sativex compared with baclofen by extending the length of
time that animals were monitored over.
4. Discussion
Cannabis has long been proposed for its eﬀects as an
antispasmodic and muscle relaxant [23]. This study provides
evidence that the cannabinoid compounds within cannabis
used to produce Sativex have the potential to dose depen-
dently inhibit spasticity in an experimental mouse model of
MS. This study also provides evidence that the antispasticity
eﬀect of Sativex treatment in this model are comparable to
the eﬀects produced by the current most commonly used
form of oral antispasticity treatment, baclofen. The vehicle
proved to be inactive, causing no reduction from baseline
in the level of spasticity in this model. Although baseline
values for flexion forces were initially higher in the vehicle
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group, it should be noted that mice were not randomized
on preassessed spasticity readings which is why initial group
means were sometimes diﬀerent as individual limbs can
vary dramatically from limb to limb and animal to animal
[18]. Furthermore, based on previously published data, the
baseline values, although varied, do not influence whether a
positive drug eﬀect can be identified [18].
Side-eﬀects of baclofen are well known and result in
limitations in its clinical application and use [24]. It is used
clinically at doses from 15mg/day up to 80mg/day, with
doses as high as 200mg/day being used safely; such a dose
represents about 3mg/kg/day. Given the rapid metabolism
in rodents, this equates to about a 10-fold diﬀerence, such
that the dose we examined in rodents would be within the
realms of human use. However, even though the dose which
has been used previously in animals [25] demonstrated
that baclofen has antispastic capability, it also presented
adverse behavioral eﬀects. In comparison, the dose of Sativex
required to provide the same antispasticity eﬀect resulted
in fewer side eﬀects with mice showing only mild sedation.
Although the diﬀerence in observable side eﬀects was quite
marked in this study, leading to the assumption that they
would also be clinically diﬀerent, it would have been helpful
to have quantified the diﬀerences seen and to have gathered
information on how the diﬀerences would translate in terms
of clinical benefit through further qualitative behavioral
testing.
Importantly, following abrupt withdrawal of baclofen in
humans, a number of significant adverse behavioural eﬀects
including visual and auditory hallucinations, convulsions
(status epilepticus), dyskinesia, confusion, psychotic, manic
or paranoid states, anxiety with tachycardia, and sweating,
and insomnia, to name a few, have been observed [26–28].
Withdrawal from baclofen treatment, therefore, requires a
slow dose reduction, over a period of several weeks, and
there are limitations with respect to the population groups
in which baclofen can be used. In particular, its use in
elderly patients and patients with cerebrovascular disorders
or a history of psychiatric illness is limited due to its
associated withdrawal symptoms. Unlike baclofen, studies
into long-term use of Sativex in patients with MS have
shown that sudden discontinuation of treatment does not
result in any significant withdrawal-like symptoms [29, 30],
although some people did report temporary changes in their
sleeping patterns, emotional status, and appetite following
discontinuation. This suggests that Sativex could be used
as a safe and eﬀective treatment alternative, since the lack
of withdrawal symptoms suggest that dependence on this
treatment is highly unlikely.
The duration of bioavailability of baclofen within the
CNS is known to have the ability to constantly activate all
GABAB receptors in the brain, causing prolonged GABAB-
mediated responses. This could explain the well-documented
dose-related side eﬀect profile of this compound and high-
lights that such first-line therapies may not be able to reach
their therapeutic potential due to lack of tolerability. As such,
the need for more eﬀective treatments still remains. Sativex
works independently of GABAB receptor mechanisms and
the most common side eﬀects reported by people taking
Sativex are dizziness and fatigue, thought to be CB1 receptor-
mediated eﬀects. These common side eﬀects of Sativex in
human studies have been shown to occur in the first four
weeks of treatment and become less frequent over time
[31]. In addition, unlike all other antispasticity medication,
Sativex is a self-titrating oromucosal medicine, allowing each
user to achieve their maximum tolerated dose alongside
symptom relief. For patients who do develop side eﬀects,
the option to reduce future doses or increase the time
between doses enables them to reduce the likelihood of
future recurrence.
Previous clinical studies have indicated that THC admin-
istered at doses between 5 and 10mg, given orally, sig-
nificantly relieved spasticity compared with placebo and
displayed a large treatment eﬀect [32, 33]. Even though these
small studies reported minimal adverse eﬀects, the belief that
the majority of Sativex-related side eﬀects are CB1 receptor
mediated, alongside the well-known psychotropic properties
of THC via CB1 receptor activity, means that THC alone
remains very limited in its clinical application. Synthetic
derivatives of THC have been produced. One clinically
available compound is nabilone, which has been investigated
and shown to relieve muscle spasms better than placebo in
the clinic; however, this study only observed a single case
[34]. As with THC, nabilone binds with high aﬃnity to the
CB1 receptor, but acts as a full agonist at CB1 whereas THC
is a partial agonist. This inevitably increases the likelihood of
adverse side eﬀects with nabilone compared to THC, again
resulting in limitations in its clinical use.
These and other studies performed over time have
indicated the potential of THC as an antispasticity agent;
however, more recent availability of standardised cannabis
medicinal extracts for preclinical and clinical research have
enabled the understanding of the therapeutic potential of
other cannabinoids, aside from THC. It has been suggested
that CBD, which is the major nonpsychoactive cannabinoid
component of cannabis, may modify the pharmacokinetics
and pharmacodynamics of THC to antagonise some of the
undesirable eﬀects caused by THC at the CB1 receptor [9,
35]. It has also been proposed that CBDmay have awakening
properties and may work as both a CB1 and CB2 receptor
antagonist [13], which in turn could counteract the potential
cannabimimetic eﬀects of THC. The mild sedation observed
with Sativex in the ABH mice at both doses, an eﬀect
consistent with THC agonism via CB1 receptors, may well be
reduced through its CBD content. Overall, the development
of Sativex, and research into the potential synergistic eﬀects
between CBD and THC coadministration may extend the
clinical application and therapeutic benefits of THC alone.
The developed tolerance of Sativex in patients may
be supported by the internal regulation of the endo-
cannabinoid system. Endocannabinoids are produced de
novo in response to physiological stimuli [36], and levels
of endocannabinoids appear to be dysregulated in vari-
ous pathologies including MS and spasticity [18]. Studies
have shown that in CREAE mice with spasticity, levels
of endocannabinoids are increased compared with normal
and nonspastic CREAE mice, providing definitive evidence
of the underlying involvement of the endocannabinoid
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system in the regulation of spasticity mechanisms [20].
The endocannabinoid system plays a role in the home-
ostasis of various endogenous functions [37], and Sativex
could potentially aﬀect the underlying involvement of the
endogenous cannabinoid system in the regulation of the
manifestations of spasticity. Further investigations into the
changes in endocannabinoid levels in response to Sativex
may lead to a greater understanding of its mechanistic
eﬀect. More recently, CBD alone has been suggested to
be an inhibitor of the primary hydrolysing enzyme of the
endocannabinoids [38], fatty acid amide hydrolase, in turn
increasing the levels of endogenous CB1 receptor agonists,
such as anandamide. This could cause further agonism of the
CB1 receptor located in presynaptic neurons, resulting in the
inhibition of neurotransmitter release, thus contributing to
the reduction in spasticity observed [39, 40].
There is good evidence that THC is a partial CB1 agonist
and that the CB1 receptor is key in the pathogenesis of spas-
ticity. In the absence of CB1 receptors, cannabinoid receptor
agonists do not elicit antispastic eﬀects [22]. Furthermore,
the use of CB1 receptor antagonists has been shown to
increase spasticity in this animal model. Abnormalities of
the endocannabinoid system have recently been shown in
MS in humans [41]. This provides mechanistic and pharma-
cological evidence that the cannabinoid constituents found
in Sativex are therapeutically beneficial in the treatment
and control of spasticity in MS, primarily via this receptor.
Another element to the CREAE model is the development
of additional MS-related symptoms including tremor and
spasticity [18]. The beneficial eﬀects of these compounds
observed in this model provide a reasonable correlation to
the treatment of spasticity as assessed in the clinic. Previous
studies looking at the eﬀect of Sativex in placebo-controlled
randomized clinical studies show it to improve the symptoms
of spasticity in MS suﬀerers [23].
5. Conclusions
The positive results from this study of Sativex in the CREAE
model of spasticity in MS, together with data obtained from
clinical studies in humans, provide increasing evidence for
the beneficial use of Sativex in humans. Sativex at a dose of
10mg/kg in this model is seen to be as eﬀective and more
importantly, elsewhere, has shown to be better tolerated
than the first-line treatment currently used for MS-related
spasticity, baclofen. Hence, we would regard Sativex to be
a potential new contender for the first-line treatment of
spasticity in patients with MS.
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